Lundbeck

Governance framework: The Board of Directors is accountable to the shareholders for the management of the company and is responsible for the overall strategy, supervision of management and ensuring that the company is organized and managed in a sound and prudent manner. The Executive Management is responsible for the day-to-day management of the company in compliance with strategy, policies and guidelines laid out by the Board of Directors. The Board of Directors consists of between five and eight members elected at the Annual General Meeting for terms of one year. The Executive Management consists of the President and CEO and other members as appointed by the Board of Directors.

At Lundbeck, we discover, develop, and commercialize treatments that make a difference to people affected by psychiatric and neurological disorders. We cover the full value chain: We have more than 70 years of experience in neuroscience and in improving the lives of people with brain disorders. We research to build a strong pipeline consisting of promising molecules and antibodies. We develop our drug candidates into new medicines. We manufacture medicines at highly advanced production sites and continue to supply our drugs to patients in need. We make our medicines available through healthcare systems in more than 100 countries. We focus our innovation within psychiatry and neurology: We are one of the few biopharmaceutical companies in the world working exclusively within neuroscience. Psychiatry covers psychotic disorders like schizophrenia, mood and anxiety disorders like depression, bipolar disorder, and post-traumatic stress disorder. Neurology covers disorders like migraine, dementia, and movement disorders like Parkinson's disease, epilepsy, and multiple system atrophy (MSA). Neuroscience is an exciting growing area with large unmet medical needs. We see growth and rapidly evolving technologies and methodologies. We are around 5,600 highly specialized employees across +50 countries. We ensure positive outcomes to people and societies: Everywhere we operate, we strive to create long-term value and make a positive contribution to people and societies. +7 million patients around the world are helped by our medicines daily. We reinvest around 20% of our revenue in R&D to continue our development of new, innovative drugs. Throughout our value chain, we incorporate patient insights by talking to and learning from those with lived experiences. We create shareholder value ensuring sustainable and profitable growth. We work in partnerships to fight stigma and address the large unmet medical needs. We act to improve health equity for the patients we serve and the communities we are part of.

Our key stakeholders: Patients are an integral part of Lundbeck's full value chain ecosystem and fundamental to our patient-centric go-to-market approach. Their lived experiences and ability to point to unmet medical needs enable us to drive focused innovation across all aspects of our business. While patients are the end-users of our pharmaceutical products, Lundbeck's customers are healthcare professionals (HCPs), including physicians and specialists, as well as authorities, such as regulatory bodies, and public and private healthcare providers. Our customers play an important role across our value chain, where HCPs are the point of contact with patients in the downstream value chain, and the authorities are regulating our access to the market. Operating in a highly regulated industry, Lundbeck has strong procedures and internal processes in place to ensure compliance with pharmaceutical regulations, achieve operational excellence and instill trust across our value chain. Leveraging our key partnerships across the value chain, including R&D, commercial and other types of partnerships, e.g., civil society and NGOs enables Lundbeck to drive our business, increase awareness and ensure societal impact. As a listed company with many investors and shareholders, Lundbeck is committed to communicating a consistent message and delivering sustainable growth. To pursue all these goals and serve people affected by brain disorders and society at large, Lundbeck relies on highly qualified and specialized employees. Furthermore, suppliers and the workers in the value chain are key to providing the fundamental inputs to produce Lundbeck's high-quality products.

-38% Reduction in Scope 1 & 2 GHG emissions since 2019. 18% Increase in Scope 3 GHG emissions since 2019.

Chemical recycling: 62% Recovery of selected organic solvents used in chemical production, compared to 59% in 2023.

We are around 5,600 highly specialized employees across +50 countries.

Underrepresented gender: 35% Gender split for senior managers globally of 35% women and 65% men, compared to 36% and 64% in 2023. Senior management is defined as Executive Vice Presidents, Senior Vice Presidents, and Vice Presidents.

Health and Safety: 3.2 Frequency of lost time accidents per 1 million working hours for all employees globally, compared to 2.8 in 2023.

Patients share their perspectives: In 2024, Lundbeck continued its 'Let the patient speak' events focusing on innovative ways of integrating patients' perspectives into our development programs. We invite patients and caregivers to share their perspectives, ultimately helping Lundbeck to incorporate insights into innovation and integrated evidence generation efforts. Lundbeck's development organization identified and implemented internal frameworks that help the company operationalize Patient-Focused Drug Development by bringing the patient voice closer to research and development efforts, describing how to seek patient input to trial designs, informing patient-centric outcome assessment strategies, and fostering an integrated, patient-centered approach to evidence development throughout the drug life cycle.

7.2 million Estimated full-year patients reached. Estimated patient years, based on 2024 sales data for Lundbeck products, excluding partner products.

Business ethics compliance: 100% Share of employees who completed the annual e-learning on our Code of Conduct, compared to 99.9% in 2023. The 100% completion rate of our annual e-learning on our Code of Conduct is a testament to this.